- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01266447
Veliparib, Topotecan Hydrochloride, and Filgrastim or Pegfilgrastim in Treating Patients With Persistent or Recurrent Cervical Cancer
A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix
Study Overview
Status
Conditions
Detailed Description
PRIMARY OBJECTIVES:
I. To estimate the antitumor activity (objective response rate by RECIST 1.1) of ABT-888 (veliparib) 10 mg administered orally twice a day on days 1 to 5 with topotecan (topotecan hydrochloride) 0.6 mg/m^2 administered IV once daily on days 1 to 5 of each cycle in patients with persistent or recurrent carcinoma of the cervix.
II. To determine the nature and degree of toxicity of ABT-888 and topotecan in patients with persistent or recurrent carcinoma of the cervix.
SECONDARY OBJECTIVES:
I. To determine the duration of progression-free survival and overall survival.
TERTIARY OBJECTIVES:
I. To determine whether evidence of an interaction exists between study treatments and tumor expression of poly(ADP-ribos)ylation of E2 protein, E6/E7 proteins, and p53R2 in relation to progression-free and overall survival or metastasis. (Translational) II. To explore the association between methylation of FanCF and BRCA in pre-treatment tumor samples and pre- and post-treatment biopsy samples and response, progression-free and overall survival of patients, and/or metastasis. (Translational)
OUTLINE:
Patients receive veliparib orally (PO) twice daily and topotecan hydrochloride intravenously (IV) over 30 minutes once daily on days 1-5. Patients also receive, according to institutional standard, filgrastim subcutaneously (SC) beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Tumor tissue samples may be collected periodically for translational studies.
After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Orange, California, United States, 92868
- UC Irvine Health/Chao Family Comprehensive Cancer Center
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Cancer Center - Anschutz Cancer Pavilion
-
-
Connecticut
-
Hartford, Connecticut, United States, 06105
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Britain, Connecticut, United States, 06050
- The Hospital of Central Connecticut
-
-
Florida
-
Orlando, Florida, United States, 32803
- Florida Hospital Orlando
-
-
Georgia
-
Savannah, Georgia, United States, 31404
- Memorial University Medical Center
-
-
Idaho
-
Boise, Idaho, United States, 83706
- Saint Alphonsus Cancer Care Center-Boise
-
-
Illinois
-
Decatur, Illinois, United States, 62526
- Decatur Memorial Hospital
-
Hinsdale, Illinois, United States, 60521
- Sudarshan K Sharma MD Limted-Gynecologic Oncology
-
Springfield, Illinois, United States, 62781
- Memorial Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University/Melvin and Bren Simon Cancer Center
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- University of Iowa/Holden Comprehensive Cancer Center
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- Johns Hopkins University/Sidney Kimmel Cancer Center
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106-0995
- Saint Joseph Mercy Hospital
-
Ann Arbor, Michigan, United States, 48106
- Michigan Cancer Research Consortium CCOP
-
Dearborn, Michigan, United States, 48124
- Oakwood Hospital and Medical Center
-
Detroit, Michigan, United States, 48236
- Saint John Hospital and Medical Center
-
Flint, Michigan, United States, 48502
- Hurley Medical Center
-
Grand Blanc, Michigan, United States, 48439
- Genesys Regional Medical Center
-
Jackson, Michigan, United States, 49201
- Allegiance Health
-
Kalamazoo, Michigan, United States, 49007
- West Michigan Cancer Center
-
Kalamazoo, Michigan, United States, 49007
- Bronson Methodist Hospital
-
Kalamazoo, Michigan, United States, 49001
- Borgess Medical Center
-
Lansing, Michigan, United States, 48912
- Sparrow Hospital
-
Livonia, Michigan, United States, 48154
- Saint Mary Mercy Hospital
-
Pontiac, Michigan, United States, 48341
- Saint Joseph Mercy Oakland
-
Port Huron, Michigan, United States, 48060
- Saint Joseph Mercy Port Huron
-
Saginaw, Michigan, United States, 48601
- Saint Mary's of Michigan
-
-
Mississippi
-
Jackson, Mississippi, United States, 39216
- University of Mississippi Medical Center
-
-
Missouri
-
Springfield, Missouri, United States, 65804
- Cancer Research for the Ozarks NCORP
-
Springfield, Missouri, United States, 65807
- CoxHealth South Hospital
-
Springfield, Missouri, United States, 65804
- Mercy Hospital Springfield
-
-
Nevada
-
Las Vegas, Nevada, United States, 89169
- Women's Cancer Center of Nevada
-
-
New Jersey
-
Camden, New Jersey, United States, 08103
- Cooper Hospital University Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87106
- Southwest Gynecologic Oncology Associates Inc
-
Albuquerque, New Mexico, United States, 87106
- University of New Mexico Cancer Center
-
-
New York
-
Brooklyn, New York, United States, 11203
- State University of New York Downstate Medical Center
-
Manhasset, New York, United States, 11030
- North Shore University Hospital
-
New Hyde Park, New York, United States, 11040
- Long Island Jewish Medical Center
-
New Hyde Park, New York, United States, 11040
- North Shore-LIJ Health System/Center for Advanced Medicine
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- Case Western Reserve University
-
Columbus, Ohio, United States, 43214
- Riverside Methodist Hospital
-
Mentor, Ohio, United States, 44060
- Lake University Ireland Cancer Center
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Health Sciences Center
-
Tulsa, Oklahoma, United States, 74146
- Oklahoma Cancer Specialists and Research Institute-Tulsa
-
-
Pennsylvania
-
Abington, Pennsylvania, United States, 19001
- Abington Memorial Hospital
-
Philadelphia, Pennsylvania, United States, 19111
- Fox Chase Cancer Center
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02905
- Women and Infants Hospital
-
-
Texas
-
Austin, Texas, United States, 78701
- University Medical Center Brackenridge
-
Dallas, Texas, United States, 75235
- Parkland Memorial Hospital
-
Dallas, Texas, United States, 75390
- UT Southwestern/Simmons Cancer Center-Dallas
-
Dallas, Texas, United States, 75390
- Clements University Hospital
-
Dallas, Texas, United States, 75235
- Zale Lipshy University Hospital
-
Temple, Texas, United States, 76508
- Scott and White Memorial Hospital
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University/Massey Cancer Center
-
-
Washington
-
Bellingham, Washington, United States, 98226
- PeaceHealth Medical Group PC
-
Bremerton, Washington, United States, 98310
- Harrison HealthPartners Hematology and Oncology-Bremerton
-
Bremerton, Washington, United States, 98310
- Harrison Medical Center
-
Everett, Washington, United States, 98201
- Providence Regional Cancer Partnership
-
Mount Vernon, Washington, United States, 98273
- Skagit Valley Hospital Regional Cancer Care Center
-
Poulsbo, Washington, United States, 98370
- Harrison HealthPartners Hematology and Oncology-Poulsbo
-
Seattle, Washington, United States, 98109
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, United States, 98109
- Seattle Cancer Care Alliance
-
Seattle, Washington, United States, 98195
- University of Washington Medical Center
-
Seattle, Washington, United States, 98104
- Pacific Gynecology Specialists
-
Seattle, Washington, United States, 98112
- Group Health Cooperative-Seattle
-
Seattle, Washington, United States, 98122-4307
- Swedish Medical Center-First Hill
-
Seattle, Washington, United States, 98133
- Northwest Hospital
-
Sequim, Washington, United States, 98384
- Olympic Medical Cancer Care Center
-
Spokane, Washington, United States, 99204
- Rockwood Cancer Treatment Center-DHEC-Downtown
-
Spokane, Washington, United States, 99202
- Cancer Care Northwest - Spokane South
-
Tacoma, Washington, United States, 98405
- MultiCare Tacoma General Hospital
-
Tacoma, Washington, United States, 98405
- Saint Joseph Medical Center
-
Walla Walla, Washington, United States, 99362
- Providence Saint Mary Regional Cancer Center
-
Wenatchee, Washington, United States, 98801
- Wenatchee Valley Hospital and Clinics
-
-
Wisconsin
-
Mukwonago, Wisconsin, United States, 53149
- D N Greenwald Center
-
Oconomowoc, Wisconsin, United States, 53066
- Oconomowoc Memorial Hospital-ProHealth Care Inc
-
Waukesha, Wisconsin, United States, 53188
- Waukesha Memorial Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients must have persistent or recurrent squamous cell carcinoma, adenosquamous carcinoma, adenocarcinoma or non-squamous cell carcinoma of the cervix with documented disease progression; histological documentation of the original primary tumor is required via the pathology report
- All patients must have measurable disease as defined by RECIST 1.1; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded); each lesion must be >= 10 mm when measured by computed tomography (CT), magnetic resonance imaging (MRI) or caliper measurement by clinical exam; or >= 20 mm when measured by chest x-ray; lymph nodes must be >= 15 mm in short axis when measured by CT or MRI
- Patient must have at least one "target lesion" to be used to assess response on this protocol as defined by RECIST 1.1; tumors within a previously irradiated field will be designated as "non-target" lesions unless progression is documented or a biopsy is obtained to confirm persistence at least 90 days following completion of radiation therapy
- Patients must not be eligible for a higher priority Gynecologic Oncology Group (GOG) protocol, if one exists; in general, this would refer to any active GOG Phase III protocol or Rare Tumor protocol for the same patient population
- Patients must have a GOG performance status of 0, 1, or 2
- Recovery from effects of recent surgery, radiotherapy, or chemotherapy
- Patients should be free of active infection requiring antibiotics
- Any hormonal therapy directed at the malignant tumor must be discontinued at least one week prior to registration; continuation of hormone replacement therapy is permitted
- Any other prior therapy directed at the malignant tumor, including chemotherapy, biologic/targeted (non-cytotoxic) therapy and immunologic agents must be discontinued at least three weeks prior to registration; all side effects must have resolved to =< grade 1 or stabilized, prior to enrolling on this study
- Any prior radiation therapy must be completed at least 4 weeks prior to registration
- Patients MUST have had one prior systemic chemotherapeutic regimen for management of advanced, metastatic, or recurrent squamous or non-squamous cell carcinoma of the cervix; chemotherapy administered concurrent with primary radiation is not counted as a systemic chemotherapy regimen (e.g.; weekly cisplatin); adjuvant chemotherapy given following the completion of radiation therapy (or concurrent chemotherapy and radiation therapy) is not counted as a systemic chemotherapy regimen (e.g.; paclitaxel and carboplatin for up to 4 cycles)
- Patients who are registered during the safety lead-in portion of this protocol are required to have prior pelvic radiation
- Patients must have NOT received more than one previous cytotoxic chemotherapy regimen (either with single or combination cytotoxic drug therapy)
- Patients are allowed to receive, but are not required to receive, biologic/targeted (non-cytotoxic) therapy as part of their one prior systemic chemotherapeutic regimen; patients are allowed to receive, but are not required to receive, biologic/targeted (non-cytotoxic) therapy for management of recurrent or persistent disease
- Patients MUST not be eligible for further curative intent surgical or pelvic radiation treatment for management of recurrent or persistent disease as determined by treating physicians
- Absolute neutrophil count (ANC) greater than or equal to 1,500/mcl
- Platelets greater than or equal to 100,000/mcl
- Creatinine less than or equal to 1.5 x institutional upper limit normal (ULN)
- Bilirubin less than or equal to 1.5 x ULN
- Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 3 x ULN
- Alkaline phosphatase less than or equal to 2.5 x ULN
- Neuropathy (sensory and motor) less than or equal to grade 1
- Patients must have signed an approved informed consent and authorization permitting release of personal health information
- Patients must meet pre-entry requirements
- Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
- Patients must have the ability to swallow pills whole
Exclusion Criteria:
- Patients are excluded who have had prior therapy with ABT-888 (veliparib), poly (ADP)-ribose polymerase inhibitors, or topotecan
- Patient with a history of other invasive malignancies, with the exception of non-melanoma skin cancer and other specific malignancies are excluded if there is any evidence of other malignancy being present within the last three years; patients are also excluded if their previous cancer treatment contraindicates this protocol therapy
- Patients who have received prior radiotherapy to any portion of the abdominal cavity or pelvis OTHER THAN for the treatment of cervical cancer within the last three years are excluded; prior radiation for localized cancer of the breast, head and neck, or skin is permitted, provided that it was completed more than three years prior to registration, and the patient remains free of recurrent or metastatic disease
- Patients who have received prior chemotherapy for any abdominal or pelvic tumor OTHER THAN for the treatment of cervical cancer within the last three years are excluded; patients may have received prior adjuvant chemotherapy for cancer, provided that it was completed more than three years prior to registration, and that the patient remains free of recurrent or metastatic disease
- Patients with seizures or history of seizures are ineligible
- Patients with history or evidence upon physical examination of central nervous system (CNS) disease, including primary brain tumor, any CNS metastases, or history of cerebrovascular accident (CVA, stroke), transient ischemic attack (TIA) or subarachnoid hemorrhage within six months of the first date of treatment on this study, are ineligible; patients with CNS metastases must be stable for > 3 months after treatment and off steroid treatment prior to study enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (veliparib, topotecan hydrochloride, filgrastim)
Patients receive veliparib PO twice daily and topotecan hydrochloride IV over 30 minutes once daily on days 1-5.
Patients also receive, according to institutional standard, filgrastim SC beginning on day 6, 7, or 8 and continuing until hematopoietic recovery or pegfilgrastim SC on day 6, 7, or 8. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
|
Correlative studies
Given SC
Other Names:
Given SC
Other Names:
Given IV
Other Names:
Given PO
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Tumor Response
Time Frame: Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicted based on symptoms or physical signs suggestive of progressive disease. The average time was 2.3 months
|
Complete and Partial Tumor Response as Assessed by RECIST 1.1.
Per Response Evaluation Criteria in Solid Tumors Criteria (RECIST v1.1), Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), at least 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion.
Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation.
|
Every other cycle for first 6 months; then every 3 months thereafter until disease progression confirmed; and at any other time if clinically indicted based on symptoms or physical signs suggestive of progressive disease. The average time was 2.3 months
|
Number of Patients With Dose-limiting Toxicities (in Safety lead-in)
Time Frame: Up to 21 days
|
A dose-limiting toxicity (DLT) is assessed by NCI CTCAE v4, occurring during cycle 1 of therapy.: A dose-limiting toxicity (DLT) is defined as either hematologic or non-hematologic toxicity assessed by NCI CTCAE v4, occurring during cycle 1 of therapy, which cause any of the following: For hematologic toxicity - dose delay of greater than 2 weeks due to failure to recover counts, Treatment related febrile neutropenia, grade 4 neutropenia lasting >7 days, treatment related grade 4 thrombocytopenia or clinically significant bleeding with grade 3 thrombocytopenia.
For non-hematologic toxicity; study treatment related grade 3 or 4 non-hematological toxicity (excluding anorexia, constipation, fatigue, hypersensitivity/allergic reaction to one of the study drugs, nausea & vomiting, and grade 3 dehydration), grade 4 nausea and vomiting for >48 hours despite maximum medical management, electrolyte imbalance of > or equal to grade 3 that can be replaced within 48 hours; any drug related death
|
Up to 21 days
|
Adverse Events (Grade 3 or Higher) During Treatment Period
Time Frame: During treatment period and up to 30 days after stopping the study treatment.The average of study treatment time was 2.3 months.
|
Number of participants with a maximum grade of 3 or higher during treatment period.
Adverse events are graded and categorized using CTCAE v4.0.
|
During treatment period and up to 30 days after stopping the study treatment.The average of study treatment time was 2.3 months.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall Survival
Time Frame: From study entry to death or last contact, up to 5 years of follow-up.
|
Overall survival is defined as the duration of time from study entry to time of death or the date of last contact.
|
From study entry to death or last contact, up to 5 years of follow-up.
|
Progression-free Survival
Time Frame: From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.
|
Progression-free survival is the period of time from study entry to time of disease progression, death or date of last contact, whichever occurs first.
Progression is defined as at least a 20% increase in the sum of the longest dimensions (LD) of target lesions taking as reference the smallest sum LD recorded since study entry, or unequivocal progression of existing non-target lesions, or the appearance of one or more new lesions, or global deterioration in health status attributable to the disease requiring a change in therapy without objective evidence of progression, or death due to disease without prior objective documentation of progression.
|
From study entry to disease progression, death or date of last contact, whichever occurs first, up to 5 years of follow-up.
|
Duration of Objective Response
Time Frame: Every other cycle for first 6 months; then every 3 months until disease progression confirmed; and at any other time if clinically indicated based on symptoms or signs suggestive of progressive disease.The average of study treatment time was 2.3 months.
|
Duration of objective response is defined as the duration from the time measurement criteria is met for partial or complete response by RECIST 1.1, whichever is first recorded, until the first date the recurrent or progressive disease is objectively documented.
Per Response Evaluation Criteria in Solid Tumors (RECIST) criteria Complete Response (CR), disappearance of all target and non-target lesions without evidence of new lesion; Partial Response (PR), at least 30% decrease in the sum of the longest dimensions (LD) of all target measurable lesions taking as reference the baseline sum of LD with no unequivocal progression of non-target lesions and no evidence of new lesion.
Complete or partial response requires confirmation at greater than or equal to 4 weeks from initial documentation.
|
Every other cycle for first 6 months; then every 3 months until disease progression confirmed; and at any other time if clinically indicated based on symptoms or signs suggestive of progressive disease.The average of study treatment time was 2.3 months.
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Charles Kunos, NRG Oncology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Respiratory Tract Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lung Diseases
- Urogenital Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Uterine Neoplasms
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Disease Attributes
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Carcinoma, Bronchogenic
- Bronchial Neoplasms
- Lung Neoplasms
- Neoplasms, Complex and Mixed
- Uterine Cervical Neoplasms
- Carcinoma
- Recurrence
- Small Cell Lung Carcinoma
- Carcinoma, Adenosquamous
- Carcinoma, Small Cell
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Antineoplastic Agents
- Immunologic Factors
- Topoisomerase Inhibitors
- Poly(ADP-ribose) Polymerase Inhibitors
- Adjuvants, Immunologic
- Topoisomerase I Inhibitors
- Lenograstim
- Veliparib
- Topotecan
Other Study ID Numbers
- NCI-2011-02659 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
- U10CA180868 (U.S. NIH Grant/Contract)
- U10CA027469 (U.S. NIH Grant/Contract)
- GOG-0127W (Other Identifier: CTEP)
- CDR0000691281
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Adenocarcinoma
-
Catalysis SLCompletedCervical Carcinoma Stage II | Cervical Carcinoma Stage III | Cervical Carcinoma Stage IV | Endometrial Adenocarcinoma Stage II | Endometrial Adenocarcinoma Stage III | Endometrial Adenocarcinoma Stage IVCuba
-
Merck Sharp & Dohme LLCCompletedPrevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in SituChina
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
-
Tampere University HospitalKarolinska Institutet; Tampere University; European UnionEnrolling by invitationCervical Intraepithelial Neoplasia Grade 2/3 | Adenocarcinoma in SituFinland
-
Shanghai Gynecologic Oncology GroupFudan UniversityCompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Malignant Neoplasm of Cervix Stage IB1 | Stage IIA1 Cervical CancerChina
-
Merck Sharp & Dohme LLCCompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Adenocarcinoma in Situ
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Human Papillomavirus Infection | Stage IVB Cervical Cancer AJCC v6 and v7United States, Canada
-
National Cancer Institute (NCI)TerminatedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Carcinoma | Cervical Carcinoma, Non-SquamousTypeUnited States
Clinical Trials on Laboratory Biomarker Analysis
-
Children's Oncology GroupNational Cancer Institute (NCI)Completed
-
ECOG-ACRIN Cancer Research GroupNational Cancer Institute (NCI)CompletedProstate Cancer
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Active, not recruitingLeukemia | Acute Lymphoblastic Leukemia | Acute Promyelocytic LeukemiaUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedUntreated Adult Acute Lymphoblastic Leukemia | Untreated Childhood Acute Lymphoblastic LeukemiaUnited States, Canada, Australia, New Zealand, Puerto Rico, Switzerland
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedChildhood Acute Lymphoblastic Leukemia in Remission | Recurrent Childhood Acute Lymphoblastic LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Completed
-
Children's Oncology GroupNational Cancer Institute (NCI)WithdrawnClear Cell Renal Cell Carcinoma | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Childhood Kidney NeoplasmUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)WithdrawnBreast Carcinoma | BRCA1 Mutation Carrier | BRCA2 Mutation CarrierUnited States
-
Children's Oncology GroupNational Cancer Institute (NCI)CompletedWilms Tumor and Other Childhood Kidney TumorsUnited States